BioCentury
ARTICLE | Emerging Company Profile

Metasyn: Declaring revolution in MRI

August 12, 1996 7:00 AM UTC

The non-invasive nature of magnetic resonance imaging and ultrasound imaging make them highly appealing as diagnostic modalities. Metasyn Inc. is focusing its initial efforts on replacement of a particularly invasive and expensive imaging method: x-ray angiography.

Magnetic resonance technology has made substantial technical progress in the past few years, driven by improvements in both software and hardware, according to Metasyn President and CEO Michael Webb, who was senior vice president of worldwide marketing and strategic planning at Ciba-Corning Diagnostics. As a result, in the Cambridge, Mass., area where the company is based, the cost of an MRI is down to $375-$400, compared to more than $1,000 a few years ago, he said. The cost of MR instrumentation also has come down: what used to be a multimillion-dollar investment is now in the range of $750,000-$1 million...